What is TECLens?
Based in Stamford, CT, TECLens is at the forefront of developing a novel, non-invasive cornea cross-linking procedure. Their proprietary 'on-eye' CXL technology, featuring a single-use disposable contact lens (CXLens®) and a compact control system, aims to treat conditions such as keratoconus, low order myopia, and presbyopia. The system's capability to treat both eyes simultaneously for keratoconus, coupled with integrated real-time ultrasound feedback and patterned ultraviolet light delivery for refractive indications, positions TECLens as a potential disruptor. The company envisions its on-eye cross-linking as a safe, simple, and permanent alternative to existing vision correction methods like LASIK, contact lenses, and eyeglasses for a vast population experiencing vision errors.
How much funding has TECLens raised?
TECLens has raised a total of $10.5M across 2 funding rounds:
Private Equity
$1.2M
Series A
$9.3M
Private Equity (2017): $1.2M, investors not publicly disclosed
Series A (2025): $9.3M led by Rimonci Capital, Yonjin Venture, Sunmed Capital, and Johnson & Johnson Innovation
Key Investors in TECLens
Rimonci Capital
Rimonci Capital is dedicated to China-Israel cross border investment, focusing on medical devices and cybersecurity. They actively seek value-created opportunities and provide intensive business development support to high-potential companies.
Yonjin Venture
Yonjin Venture expresses interest in innovative technologies within therapeutics, diagnostics, and medical devices, aligning with TECLens' focus on advanced medical solutions.
Sunmed Capital
Sunmed Capital operates within the Venture Capital & Private Equity industry, suggesting a strategic interest in funding companies with high growth potential in the medical technology sector.
What's next for TECLens?
With this substantial strategic investment, TECLens is poised to accelerate its development and commercialization efforts. The company's focus on a clinical-stage, non-invasive medical device suggests a trajectory towards further clinical trials, regulatory approvals, and market penetration. The enterprise-level funding indicates a transition towards scaling operations and potentially expanding its therapeutic applications beyond initial targets. Investors backing TECLens are likely anticipating significant market adoption driven by the demand for advanced, less invasive vision correction solutions.
See full TECLens company page
